National Cancer Institute NCI Cancer Bulletin: A Trusted Source for Cancer Research News
September 7, 2010 • Volume 7 / Number 17


PET scans for patient with advanced melanoma at baseline and after 2 weeks of treatment with PLX4032. Targeted Drug for Melanoma Shows Promise in Early Clinical Testing

The vast majority of patients with advanced melanoma who received an experimental targeted drug called PLX4032 responded to the treatment in a phase I clinical trial, researchers announced last month. The drug targets a common genetic change in melanoma tumors, and 26 of 32 patients (81 percent) who were treated with the recommended phase II dose had a partial or complete response. The tumors of some patients shrank or even went away, at least temporarily. Read more > >


Inside NCI: A Conversation with Dr. Crystal Mackall about Pediatric Oncology Article contains video

Watch the Inside NCI videoThe chief of NCI’s Pediatric Oncology Branch talks about the research in her lab at NCI and areas where pediatric cancer researchers are poised to make major advances. Read more > >



Bulletin Survey to Launch September 14

Readers who subscribe to the NCI Cancer Bulletin will receive an e-mail message next Tuesday with a hyperlinked invitation to participate in our biannual survey. The survey is a tool we use to learn about what you like the most about our newsletter and what we can change to better suit your needs. The survey will be active for 3 weeks, so don’t miss your chance to participate.



  • Notes

    • NCAB Meeting Begins Today
    • New Grants Awarded for Biomarker Discovery and Validation
    • Federal Committee Will Establish Breast Cancer Research Agenda
    • Glasgow Named DCCPS Deputy Director
    • Groundbreaking Ceremony Held for NCI’s Future Satellite Campus
    • New Brochure on Cancer Genomics Available

Selected articles from past issues of the NCI Cancer Bulletin are available in Spanish.

The NCI Cancer Bulletin is produced by the National Cancer Institute (NCI), which was established in 1937. Through basic, clinical, and population-based biomedical research and training, NCI conducts and supports research that will lead to a future in which we can identify the environmental and genetic causes of cancer, prevent cancer before it starts, identify cancers that do develop at the earliest stage, eliminate cancers through innovative treatment interventions, and biologically control those cancers that we cannot eliminate so they become manageable, chronic diseases.

For more information about cancer, call 1-800-4-CANCER or visit

NCI Cancer Bulletin staff can be reached at

Next Section >